Edwards Lifesciences Corp (EW) caused an inflection in the market, with anticipated robust
TAVR growth expected to drive Q3 earnings. The possibility of launching its
Next-Gen Heart Valve in Thailand sees potential to shape its growth outlook. EW has seen interest from institutional investors like
Aberdeen Group and
Fulcrum Capital, whose bullish positioning led to increased stakes. Alongside these developments,
Rosen Law Firm investigates potential breaches in Edwards Lifesciences. The launch of a
$500M accelerated share buyback adds further credence to Edwards Lifesciences' potential success. EW has managed to achieve better-than-expected results for Q2 2025 with
EPS beating expectations. Scrutiny over growth disclosures hasn't deterred the positive sentiment amongst several analysts, and has resulted in a several upgrades for EW from
Evercore ISI. Concerns have been raised over FTC’s legal actions to stall the proposed acquisition with
JenaValve. However, the Q2 earnings remain strong and the potential launch of
SAPIEN X4 Valve could change the game in heart valve treatment.
Edwards Lifesciences Corp EW News Analytics from Fri, 20 Dec 2024 08:00:00 GMT to Fri, 17 Oct 2025 12:47:21 GMT -
Rating 6
- Innovation 1
- Information 8
- Rumor -4
